Compare EHang Holdings Ltd - ADR (EH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

EHang Holdings (EH) trades at $4.19, up 1.21% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with strong revenue growth from $44M in 2022 to $418M in 2025, but deep losses persist with a -66% net margin. Recent news includes regulatory investigations and international expansion into Vietnam, creating conflicting sentiment signals for investors.

Outlook remains challenging with significant execution risks and negative profitability, though the eVTOL market offers long-term potential. The stock faces headwinds from regulatory scrutiny and cash burn, requiring careful risk assessment despite trading near technical support levels.

Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.

The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.